Glycoprotein News and Research

RSS

Basigin/CD147 discarded as an accessory SARS-CoV-2 binding receptor

By using specialized assays customized to detect specific receptor interactions, researchers from the Wellcome Sanger Institute in Cambridge UK find no evidence for direct binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to a transmembrane glycoprotein known as basigin.

28 Jul 2020

AI Therapeutics announces start of Phase II clinical trial of potential COVID-19 treatment

AI Therapeutics announced the start of Phase II clinical trial for the treatment of newly diagnosed COVID-19 patients in collaboration with Yale University.

27 Jul 2020

High ACE2 Expression on pancreatic islet cells during inflammation could explain new-onset diabetes in COVID-19

A new study suggests that the SARS-CoV-2 infection may be linked to the onset of diabetes, via the infection of pancreatic islet beta cells, which produce insulin.

27 Jul 2020

Neo-self antibody could be a major cause of recurrent pregnancy loss

A research group centered around Kobe University Graduate School of Medicine's Professor YAMADA Hideto and Associate Professor TANIMURA Kenji (Department of Obstetrics and Gynecology), and Professor ARASE Hisashi et al. of Osaka University's Research Institute for Microbial Diseases (RIMD) have revealed for the first time in the world the high frequency of a novel autoantibody in women suffering from recurrent pregnancy loss.

23 Jul 2020

Scientists isolate potent SARS-CoV-2 neutralizing antibodies from COVID-19 patients

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing the SARS-CoV-2 virus.

22 Jul 2020

Pfizer/BioNTech COVID-19 vaccine elicits both neutralizing antibodies and T cell response

A new study published on the preprint server medRxiv by a research group from the U.S. and Germany indicates that a novel BNT162b1 RNA-based vaccine against coronavirus disease (COVID-19) induces functional and proinflammatory T cell responses in almost all participants – marking another landmark achievement for this promising vaccine candidate.

21 Jul 2020

Analysis of the SARS-CoV-2 proteome via visual tools

Now, a new study published on the preprint server bioRxiv* in July 2020 shows how this can be advanced at a greater speed by combining experimental results with homology models obtained by high-throughput pipelines. This will help produce new hypotheses that will show novel druggable targets for effective drug development.

21 Jul 2020

An abundance of biomolecules linked to COVID-19 status and severity

Tapping into the potential of the multi-omic method to uncover functional connections between various classes of biomolecules, researchers from notable institutions in the United States have discovered sets of co-varying molecules that shed light on coronavirus disease (COVID-19) pathophysiology and provide treatment opportunities.

20 Jul 2020

Involvement of nicotine receptors in COVID-19

Researchers from the University of Bristol, Oxford Brookes University and the University of California San Diego neatly demonstrated how the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibits high affinity for nicotinic acetylcholine receptors (nAChRs), with significant implications for coronavirus disease (COVID-19) pathology and infectivity. Their findings are published on the bioRxiv* preprint server.

20 Jul 2020

Oxford University and AstraZeneca to publish eagerly-anticipated COVID-19 trial results today

The coronavirus pandemic is still rapidly spreading across the globe, infecting more than 14.44 million people. With more than 188 countries and territories affected, scientists are racing to develop a vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19).

19 Jul 2020

New insight into the SARS-CoV-2 infection process

Canadian researchers from the Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, have found that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be using a unique method to gain entry into the cells.

16 Jul 2020

Study shows fused lung cells are pervasive in severe COVID-19

In a recent bioRxiv paper, scientists from Institut Pasteur and other research centers in France demonstrated how pathological effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are modulated by cellular proteins that can either inhibit or facilitate cell fusion and subsequent syncytia formation.

16 Jul 2020

Common FDA-approved drug may be a powerful tool in fighting COVID-19

A common drug, already approved by the Food and Drug Administration, may also be a powerful tool in fighting COVID-19, according to research published this week in Antiviral Research.

15 Jul 2020

Mobility and flexibility in SARS-CoV-2 proteins

Now, a new study published on the preprint server bioRxiv in July 2020 describes the use of in silico modeling of potential drug targets on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein structures, using data retrieved from the Protein Databank (PDB).

15 Jul 2020

Absolute Antibody and University of Zurich partner to offer novel SARS-CoV-2 sybodies

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced a partnership with University of Zurich to offer synthetic nanobodies against the receptor binding domain (RBD) of SARS-CoV-2, the coronavirus that causes COVID-19.

From Absolute Antibody Ltd 14 Jul 2020

A new measles-based COVID-19 vaccine

Now, a new study by researchers from Germany's Paul Ehrlich Institute and published on the preprint server bioRxiv in July 2020 describes a potential vaccine based on the measles vaccine, which elicits both an antibody response and cellular immunity against the virus. This also protects against the measles virus. This could be a significant weapon in the fight against these two threats.

14 Jul 2020

Researchers stabilize the closed SARS-CoV-2 spike trimer

Now, a new study by researchers at Janssen Vaccines & Prevention BV and Leiden University and published on the preprint server bioRxiv uses cryoEM to reveal the structure of this trimer, in order to support both vaccine development and diagnostic testing based on antibody production.

14 Jul 2020

Study identifies three novel broad-spectrum SARS-CoV-2 cell entry inhibitors

Researchers from the National Institutes of Health (NIH) and Cornell University in the U.S. just described several new inhibitors of human coronavirus spike proteins by screening a library of approved drugs with SARS-S and MERS-S pseudotyped particle entry assays. Their exciting findings are currently available on the bioRxiv preprint server.

13 Jul 2020

As winter comes other viruses will compete with SARS-CoV-2 for susceptible hosts

A new study published on the preprint server medRxiv in July 2020 traces how COVID-19 became the predominant cause of respiratory infection in the period from early January until the present.

10 Jul 2020

Study of glycosylation on SARS-CoV-2 spike protein

The first intimation of the current COVID-19 crisis came with the news of severe pneumonic illness caused by an unknown agent in a Chinese city called Wuhan, issued on the last day of 2019. Following this, researchers found the cause to be a novel coronavirus, closely related to the earlier SARS virus, now called severe acute respiratory syndrome coronavirus 2.

8 Jul 2020